Literature DB >> 24018805

Intraductal carcinoma of the prostate: the whole story.

Ming Zhou1.   

Abstract

Intraductal carcinoma of the prostate (IDC-P) is characterised by proliferation of malignant secretory cells that markedly expand prostatic ducts and acini. Its morphological features and diagnostic criteria have been refined in recent studies. Its molecular characteristics have also been increasingly elucidated. IDC-P is strongly associated with high grade and high volume invasive prostate cancer and unfavourable clinical outcomes. Therefore, it is critical to recognise and report IDC-P, especially in prostate biopsies where the clinical implications of the diagnosis are greatest. IDC-P has to be distinguished from several other prostate lesions with similar histological appearance. The distinction between IDC-P and high grade prostatic intraepithelial neoplasia is most important as they have drastically different implications for patient management. IDC-P is an uncommon finding in prostate biopsies, and is even rarer as an isolated finding without concomitant prostate cancer in biopsies. However, patients with isolated IDC-P in biopsies are recommended for either definitive treatment or immediate repeat biopsy. This article will review the historical aspect, diagnostic criteria, molecular genetics, and clinical significance of IDC-P.

Entities:  

Mesh:

Year:  2013        PMID: 24018805     DOI: 10.1097/PAT.0b013e3283653322

Source DB:  PubMed          Journal:  Pathology        ISSN: 0031-3025            Impact factor:   5.306


  7 in total

Review 1.  [Intraductal carcinoma of the prostate].

Authors:  G Kristiansen; M Varma; G Seitz
Journal:  Pathologe       Date:  2016-02       Impact factor: 1.011

2.  Coordinate loss of MAP3K7 and CHD1 promotes aggressive prostate cancer.

Authors:  Lindsey Ulkus Rodrigues; Leah Rider; Cera Nieto; Lina Romero; Anis Karimpour-Fard; Massimo Loda; M Scott Lucia; Min Wu; Lihong Shi; Adela Cimic; S Joseph Sirintrapun; Rosalie Nolley; Colton Pac; Haitao Chen; Donna M Peehl; Jianfeng Xu; Wennuan Liu; James C Costello; Scott D Cramer
Journal:  Cancer Res       Date:  2015-03-15       Impact factor: 12.701

3.  Intraductal prostate cancer: An aggressive subset of prostate cancers? Immunophenotypic evaluation.

Authors:  Pinuccia Faviana; Beatrice Belgio; Marco Panichi; Francesca Manassero; Cesare Selli; Laura Boldrini
Journal:  Urol Ann       Date:  2022-04-18

4.  The presence of intraductal carcinoma of the prostate in needle biopsy is a significant prognostic factor for prostate cancer patients with distant metastasis at initial presentation.

Authors:  Masashi Kato; Toyonori Tsuzuki; Kyosuke Kimura; Akihiro Hirakawa; Fumie Kinoshita; Naoto Sassa; Ryo Ishida; Akitoshi Fukatsu; Tohru Kimura; Yasuhito Funahashi; Yoshihisa Matsukawa; Ryohei Hattori; Momokazu Gotoh
Journal:  Mod Pathol       Date:  2016-01-08       Impact factor: 7.842

Review 5.  Intraductal Carcinoma of the Prostate Gland: Recent Advances.

Authors:  Mukul K Divatia; Jae Y Ro
Journal:  Yonsei Med J       Date:  2016-09       Impact factor: 2.759

6.  The presence of intraductal carcinoma of the prostate is closely associated with poor prognosis: a systematic review and meta-analysis.

Authors:  Yu-Cong Zhang; Guo-Liang Sun; De-Lin Ma; Chao Wei; Hao-Jie Shang; Zhuo Liu; Rui Li; Tao Wang; Shao-Gang Wang; Ji-Hong Liu; Xia-Ming Liu
Journal:  Asian J Androl       Date:  2021 Jan-Feb       Impact factor: 3.285

Review 7.  Intraductal carcinoma of the prostate.

Authors:  Eszter Szentirmai; Giovanna Angela Giannico
Journal:  Pathologica       Date:  2020-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.